Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves

John C. Morrill, Richard C. Laughlin, Nandadeva Lokugamage, Jing Wu, Roberta Pugh, Pooja Kanani, L. Garry Adams, Shinji Makino, C. J. Peters

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The safety and immunogenicity of an authentic recombinant (ar) of the live, attenuated MP-12 Rift Valley fever (RVF) vaccine virus with a large deletion of the NSm gene in the pre-Gn region of the M RNA segment (arMP-12δNSm21/384) was tested in 4-6 month old Bos taurus calves. Phase I of this study evaluated the neutralizing antibody response, measured by 80% plaque reduction neutralization (PRNT80), and clinical response of calves to doses of 1×101 through 1×107 plaque forming units (PFU) administered subcutaneously (s.c.). Phase II evaluated the clinical and neutralizing antibody response of calves inoculated s.c. or intramuscularly (i.m.) with 1×103, 1×104 or 1×105PFU of arMP-12δNSm21/384. No significant adverse clinical events were observed in the animals in these studies. Of all specimens tested, only one vaccine viral isolate was recovered and that virus retained the introduced deletion. In the Phase I study, there was no statistically significant difference in the PRNT80 response between the dosage groups though the difference in IgG response between the 1×101PFU group and the 1×105PFU group was statistically significant (p<0.05). The PRNT80 response of the respective dosage groups corresponded to dose of vaccine with the 1×101PFU dose group showing the least response. The Phase II study also showed no statistically significant difference in PRNT80 response between the dosage groups though the difference in RVFV-specific IgG values was significantly increased (p<0.001) in animals inoculated i.m. with 1×104 or 1×105PFU versus those inoculated s.c. with 1×103 or 1×105PFU. Although the study groups were small, these data suggest that 1×104 or 1×105PFU of arMP-12δNSm21/384 administered i.m. to calves will consistently stimulate a presumably protective PRNT80 response for at least 91 days post inoculation. Further studies of arMP-12δNSm21/384 are warranted to explore its suitability as an efficacious livestock vaccine.

Original languageEnglish (US)
Pages (from-to)4988-4994
Number of pages7
JournalVaccine
Volume31
Issue number43
DOIs
StatePublished - Oct 9 2013

Fingerprint

Rift Valley Fever
Rift Valley fever
Vaccines
immune response
calves
vaccines
Neutralizing Antibodies
Antibody Formation
dosage
Immunoglobulin G
Rift Valley fever virus
Viral Vaccines
Gene Deletion
Livestock
neutralizing antibodies
RNA
Viruses
Safety
viruses
gene deletion

Keywords

  • ArMP-12δNSm21/384
  • Calves
  • Rift Valley fever
  • RVF MP-12-NSm deletion vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Morrill, J. C., Laughlin, R. C., Lokugamage, N., Wu, J., Pugh, R., Kanani, P., ... Peters, C. J. (2013). Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine, 31(43), 4988-4994. https://doi.org/10.1016/j.vaccine.2013.08.003

Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. / Morrill, John C.; Laughlin, Richard C.; Lokugamage, Nandadeva; Wu, Jing; Pugh, Roberta; Kanani, Pooja; Adams, L. Garry; Makino, Shinji; Peters, C. J.

In: Vaccine, Vol. 31, No. 43, 09.10.2013, p. 4988-4994.

Research output: Contribution to journalArticle

Morrill, JC, Laughlin, RC, Lokugamage, N, Wu, J, Pugh, R, Kanani, P, Adams, LG, Makino, S & Peters, CJ 2013, 'Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves', Vaccine, vol. 31, no. 43, pp. 4988-4994. https://doi.org/10.1016/j.vaccine.2013.08.003
Morrill JC, Laughlin RC, Lokugamage N, Wu J, Pugh R, Kanani P et al. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine. 2013 Oct 9;31(43):4988-4994. https://doi.org/10.1016/j.vaccine.2013.08.003
Morrill, John C. ; Laughlin, Richard C. ; Lokugamage, Nandadeva ; Wu, Jing ; Pugh, Roberta ; Kanani, Pooja ; Adams, L. Garry ; Makino, Shinji ; Peters, C. J. / Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. In: Vaccine. 2013 ; Vol. 31, No. 43. pp. 4988-4994.
@article{249508bd50da4b8b8ec6637eda1492ea,
title = "Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves",
abstract = "The safety and immunogenicity of an authentic recombinant (ar) of the live, attenuated MP-12 Rift Valley fever (RVF) vaccine virus with a large deletion of the NSm gene in the pre-Gn region of the M RNA segment (arMP-12δNSm21/384) was tested in 4-6 month old Bos taurus calves. Phase I of this study evaluated the neutralizing antibody response, measured by 80{\%} plaque reduction neutralization (PRNT80), and clinical response of calves to doses of 1×101 through 1×107 plaque forming units (PFU) administered subcutaneously (s.c.). Phase II evaluated the clinical and neutralizing antibody response of calves inoculated s.c. or intramuscularly (i.m.) with 1×103, 1×104 or 1×105PFU of arMP-12δNSm21/384. No significant adverse clinical events were observed in the animals in these studies. Of all specimens tested, only one vaccine viral isolate was recovered and that virus retained the introduced deletion. In the Phase I study, there was no statistically significant difference in the PRNT80 response between the dosage groups though the difference in IgG response between the 1×101PFU group and the 1×105PFU group was statistically significant (p<0.05). The PRNT80 response of the respective dosage groups corresponded to dose of vaccine with the 1×101PFU dose group showing the least response. The Phase II study also showed no statistically significant difference in PRNT80 response between the dosage groups though the difference in RVFV-specific IgG values was significantly increased (p<0.001) in animals inoculated i.m. with 1×104 or 1×105PFU versus those inoculated s.c. with 1×103 or 1×105PFU. Although the study groups were small, these data suggest that 1×104 or 1×105PFU of arMP-12δNSm21/384 administered i.m. to calves will consistently stimulate a presumably protective PRNT80 response for at least 91 days post inoculation. Further studies of arMP-12δNSm21/384 are warranted to explore its suitability as an efficacious livestock vaccine.",
keywords = "ArMP-12δNSm21/384, Calves, Rift Valley fever, RVF MP-12-NSm deletion vaccine",
author = "Morrill, {John C.} and Laughlin, {Richard C.} and Nandadeva Lokugamage and Jing Wu and Roberta Pugh and Pooja Kanani and Adams, {L. Garry} and Shinji Makino and Peters, {C. J.}",
year = "2013",
month = "10",
day = "9",
doi = "10.1016/j.vaccine.2013.08.003",
language = "English (US)",
volume = "31",
pages = "4988--4994",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "43",

}

TY - JOUR

T1 - Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves

AU - Morrill, John C.

AU - Laughlin, Richard C.

AU - Lokugamage, Nandadeva

AU - Wu, Jing

AU - Pugh, Roberta

AU - Kanani, Pooja

AU - Adams, L. Garry

AU - Makino, Shinji

AU - Peters, C. J.

PY - 2013/10/9

Y1 - 2013/10/9

N2 - The safety and immunogenicity of an authentic recombinant (ar) of the live, attenuated MP-12 Rift Valley fever (RVF) vaccine virus with a large deletion of the NSm gene in the pre-Gn region of the M RNA segment (arMP-12δNSm21/384) was tested in 4-6 month old Bos taurus calves. Phase I of this study evaluated the neutralizing antibody response, measured by 80% plaque reduction neutralization (PRNT80), and clinical response of calves to doses of 1×101 through 1×107 plaque forming units (PFU) administered subcutaneously (s.c.). Phase II evaluated the clinical and neutralizing antibody response of calves inoculated s.c. or intramuscularly (i.m.) with 1×103, 1×104 or 1×105PFU of arMP-12δNSm21/384. No significant adverse clinical events were observed in the animals in these studies. Of all specimens tested, only one vaccine viral isolate was recovered and that virus retained the introduced deletion. In the Phase I study, there was no statistically significant difference in the PRNT80 response between the dosage groups though the difference in IgG response between the 1×101PFU group and the 1×105PFU group was statistically significant (p<0.05). The PRNT80 response of the respective dosage groups corresponded to dose of vaccine with the 1×101PFU dose group showing the least response. The Phase II study also showed no statistically significant difference in PRNT80 response between the dosage groups though the difference in RVFV-specific IgG values was significantly increased (p<0.001) in animals inoculated i.m. with 1×104 or 1×105PFU versus those inoculated s.c. with 1×103 or 1×105PFU. Although the study groups were small, these data suggest that 1×104 or 1×105PFU of arMP-12δNSm21/384 administered i.m. to calves will consistently stimulate a presumably protective PRNT80 response for at least 91 days post inoculation. Further studies of arMP-12δNSm21/384 are warranted to explore its suitability as an efficacious livestock vaccine.

AB - The safety and immunogenicity of an authentic recombinant (ar) of the live, attenuated MP-12 Rift Valley fever (RVF) vaccine virus with a large deletion of the NSm gene in the pre-Gn region of the M RNA segment (arMP-12δNSm21/384) was tested in 4-6 month old Bos taurus calves. Phase I of this study evaluated the neutralizing antibody response, measured by 80% plaque reduction neutralization (PRNT80), and clinical response of calves to doses of 1×101 through 1×107 plaque forming units (PFU) administered subcutaneously (s.c.). Phase II evaluated the clinical and neutralizing antibody response of calves inoculated s.c. or intramuscularly (i.m.) with 1×103, 1×104 or 1×105PFU of arMP-12δNSm21/384. No significant adverse clinical events were observed in the animals in these studies. Of all specimens tested, only one vaccine viral isolate was recovered and that virus retained the introduced deletion. In the Phase I study, there was no statistically significant difference in the PRNT80 response between the dosage groups though the difference in IgG response between the 1×101PFU group and the 1×105PFU group was statistically significant (p<0.05). The PRNT80 response of the respective dosage groups corresponded to dose of vaccine with the 1×101PFU dose group showing the least response. The Phase II study also showed no statistically significant difference in PRNT80 response between the dosage groups though the difference in RVFV-specific IgG values was significantly increased (p<0.001) in animals inoculated i.m. with 1×104 or 1×105PFU versus those inoculated s.c. with 1×103 or 1×105PFU. Although the study groups were small, these data suggest that 1×104 or 1×105PFU of arMP-12δNSm21/384 administered i.m. to calves will consistently stimulate a presumably protective PRNT80 response for at least 91 days post inoculation. Further studies of arMP-12δNSm21/384 are warranted to explore its suitability as an efficacious livestock vaccine.

KW - ArMP-12δNSm21/384

KW - Calves

KW - Rift Valley fever

KW - RVF MP-12-NSm deletion vaccine

UR - http://www.scopus.com/inward/record.url?scp=84885184339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885184339&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.08.003

DO - 10.1016/j.vaccine.2013.08.003

M3 - Article

VL - 31

SP - 4988

EP - 4994

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -